Furthermore, another more recent study by our group indicated that long-term treatment of lapatinib in triple-negative breast cancer cells increases IL6 expression through miRNA-7-dependent activation of Raf-1 signaling [39]. The gene discussed is IL6; the disease is triple-negative breast carcinoma.